



February 13, 2017

Argos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium

Company to present a poster on the development of immunotherapy for muscle invasive bladder cancer

DURHAM, N.C., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the **Arcelis®** precision immunotherapy technology platform, today announced that the company will present at the 2017 Genitourinary Cancers Symposium being held February 16-18 at the Rosen Shingle Creek in Orlando, FL.

Irina Tcherepanova, Ph.D., senior director of research and development for Argos, will review a poster titled, "Development of a novel immunotherapy for muscle invasive bladder cancer (MIBC)," during Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer on Saturday, February 18 from 7:00-7:55am ET and 11:30am-1:00pm ET.

The 2017 Genitourinary Cancers Symposium is a three-day scientific and educational meeting cosponsored by the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO). For more information, visit <http://gucasym.org/>.

About the Arcelis® Technology Platform

Arcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient's individual disease. It is designed to overcome immunosuppression by producing a specifically targeted, durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The **Arcelis®** process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient's own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient's plasma, and administered via intradermal injection as an individualized immunotherapy.

About Argos Therapeutics

Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its **Arcelis®** technology platform. Argos' most advanced product candidate, **rocapuldencel-T**, is being evaluated in the pivotal **ADAPT Phase 3** clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, **rocapuldencel-T** is being studied in **Phase 2** investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate **Arcelis®**-based product candidate, **AGS-004**, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated **Phase 2** clinical trial aimed at HIV eradication in adult patients.

Forward Looking Statements

Any statements in this press release about Argos' future expectations, plans and prospects, including statements about the expected use of the leased manufacturing space, Argos' financial prospects, future operations and sufficiency of funds for future operations, clinical development of Argos' product candidates, expectations regarding future clinical trials and future expectations and plans and prospects for Argos and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "may," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund its continuing operations for the periods anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Argos' product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; whether Argos can successfully establish commercial manufacturing operations on a timely basis or at all; and other factors discussed in the "Risk Factors" section of Argos' Form 10-Q for the quarter ended September 30, 2016, which is on file with

the SEC, and in other filings Argos makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Argos' views as of the date hereof. Argos anticipates that subsequent events and developments will cause Argos' views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos' views as of any date subsequent to the date hereof.

Media contact:

Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

Investor contact:

John Menditto
Argos Therapeutics, Inc.
919-908-0687
jmenditto@argostherapeutics.com